However, this marked efficacy was accompanied with increased bile duct proliferation and increased inflammation, cautioning the safety of the combination of FGF19 and PPARα activation in the treatment of obesity and MASLD. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.